Citrus junos Tanaka Peel Extract Ameliorates HDM-Induced Lung Inflammation and Immune Responses In Vivo

In the wake of the COVID-19 pandemic, lung disorders have become a major health concern for humans. Allergic asthma is the most prevalent form of asthma, and its treatments target the inflammation process. Despite significant developments in the diagnosis and management of allergic asthma, side effects are a major concern. Additionally, its extreme heterogeneity impedes the efficacy of the majority of treatments. Thus, newer, safer therapeutic substances, such as natural products, are desired. Citrus junos Tanaka has traditionally been utilized as an anti-inflammatory, sedative, antipyretic, and antitoxic substance. In this study, the protective effects of Citrus junos Tanaka peel extract (B215) against lung inflammation were examined, and efforts were made to understand the underlying protective mechanism using an HDM-induced lung inflammation murine model. The administration of B215 reduced immune cell infiltration in the lungs, plasma IgE levels, airway resistance, mucus hypersecretions, and cytokine production. These favorable effects alleviated HDM-induced lung inflammation by modulating the NF-kappa B signaling pathway. Hence, B215 might be a promising functional food to treat lung inflammation without adverse effects.

Automated summary

With the COVID-19 pandemic, lung disorders have become a significant concern. The most common form of asthma, allergic asthma, is targeted by treatments that address inflammation. However, side effects and the heterogeneity of the condition limit the effectiveness of current treatments. This study examined the protective effects of Citrus junos Tanaka peel extract (B215) on lung inflammation and found that it reduced immune cell infiltration, plasma IgE levels, airway resistance, mucus hypersecretion, and cytokine production. These findings suggest that B215 could be a promising functional food for treating lung inflammation without adverse effects.